Key Market Insights

• Presently, more than 70 companies claim to have the required expertise to offer various services for the synthesis and manufacturing of mRNAs across different scales of operations, worldwide
• In pursuit of building a competitive edge, service providers are actively upgrading their existing capabilities to enhance their respective portfolios and comply with the evolving industry benchmarks
• Leveraging their expertise, stakeholders in this domain are providing contract manufacturing services for a myriad of mRNA-based products
• Presently, more than 95 kits are available in the market for the synthesis of research grade mRNAs used for various applications with yield range up to 50,000 µgs
• Close to 50% of mRNA synthesis kits contain all the components, including enzyme mix, buffers and other reagents, required for the synthesis of varying quantity of modified mRNAs at affordable prices
• mRNA synthesis kit providers are steadily expanding their capabilities in order to enhance their existing capabilities and augment their respective kit portfolios
• A case study of considerable increase in the number of clinical trials registered for mRNA-based therapeutics / vaccines shows growing demand for such therapeutic / preventive interventions
• The growing interest is evident from the rise in partnership activity; in fact, the maximum number of collaborations related to mRNA-based drug manufacturing were inked in 2020 and 2021
• Close to 35 mRNA-based therapeutic / vaccine developers across the world are anticipated to forge strategic alliances with mRNA synthesis and mRNA manufacturing service providers, to further augment their drug portfolio
• In order to tap the lucrative opportunity in this rapidly growing market, big pharma players have undertaken several initiatives, including strengthening product portfolio, agreements, and investments
• The market’s evolution is likely to be driven by the need for novel mRNA therapeutics; we expect the future opportunity to be well distributed across various types of product, therapeutic areas, and key geographical regions

1. PREFACE

1.1.      Scope of the Report

1.2.      Market Segmentations

1.3.      Research Methodology

1.4.      Key Questions Answered

1.5.      Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1.      An Overview of mRNA

3.2.      Structure of mRNA

3.3.      Evolution of mRNA Vaccines

3.4.      mRNA Manufacturing Process

3.4.1.   Chemical Synthesis of mRNA

3.4.2.   In vitro Synthesis of mRNA

3.5.      Applications of Chemically / in vitro Synthesized mRNA

3.6.      Challenges Associated with mRNA Synthesis

3.7.      Commonly Outsourced Manufacturing Operations

3.8.      Advantages of Outsourcing Manufacturing Operations

4. MARKET LANDSCAPE: mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS

4.1.      mRNA Custom Synthesis Service Providers: Overall Market Landscape

4.1.1.   Analysis by Year of Establishment

4.1.2.   Analysis by Company Size

4.1.3.   Analysis by Location of Headquarters

4.1.4.   Analysis by Company Size and Location of Headquarters

4.1.5.   Analysis by Type of Service(s) Offered

4.1.6.   Analysis by Input for Synthesis

4.1.7.   Analysis by Structural Modification

4.1.8.   Analysis by Type of Purification Method(s)

4.1.9.   Analysis by Application Area(s)

4.1.10.             Analysis by Scale of Operation

4.1.11.             mRNA Custom Synthesis Service Providers: Information on Length (Base Pair) of mRNA       Manufactured

4.1.12.             mRNA Custom Synthesis Service Providers: Information on mRNA Synthesis / Manufacturing Capacity

5. mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS

5.1.      Key Parameters and Scores

5.2.      Methodology

5.3.      Competitiveness Analysis: Small Companies

5.4.      Competitiveness Analysis: Mid-Sized Companies

5.5.      Competitiveness Analysis: Large Companies

6. MARKET LANDSCAPE: mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS

6.1.      mRNA Contract Manufacturing Service Providers: Overall Market Landscape

6.1.1.   Analysis by Year of Establishment

6.1.2.   Analysis by Company Size

6.1.3.   Analysis by Location of Headquarters

6.1.4.   Analysis by Company Size and Location of Headquarters

6.1.5.   Analysis by Location of Manufacturing Facility

6.1.6.   Analysis by Type of Product(s) Manufactured

6.1.7.   Analysis by Type of Service(s) Offered

6.1.8.   Analysis by Scale of Operation

7. mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS

7.1.      Methodology

7.2.      Company Competitiveness Analysis: mRNA Contract Manufacturing Service Providers based in North America

7.3.      Company Competitiveness Analysis: mRNA Contract Manufacturing Service Providers based in Europe

7.4.      Company Competitiveness Analysis: mRNA Contract Manufacturing Service Providers based in Asia-Pacific

8. MARKET LANDSCAPE: mRNA SYNTHESIS KIT PROVIDERS

8.1.      mRNA Synthesis Kits: Overall Market Landscape

8.1.1.   Analysis by Kit Components

8.1.2.   Analysis by Type of Enzyme

8.1.3.   Analysis by Type of Enzyme Mix Used

8.1.4.   Analysis by mRNA Component Modified

8.1.5.   Analysis by Yield per Reaction

8.1.6.   Analysis by Number of Reactions

8.1.7.   Analysis by Reaction Run-Time

8.1.8.   Analysis by Price of Kits

8.1.9.   Most Active Players: Analysis by Number of mRNA Synthesis Kits Offered

8.2.      mRNA Synthesis Kits: Developer Landscape

8.2.1.   Analysis by Year of Establishment

8.2.2.   Analysis by Company Size

8.2.3.   Analysis by Location of Headquarters

9. mRNA SYNTHESIS KITS: PRODUCT COMPETITIVENESS ANALYSIS

9.1.      Methodology

9.2.      Product Competitiveness Analysis: mRNA Synthesis Kits

10. COMPANY PROFILES: mRNA SYNTHESIS AND MANUFACTURING SERVICE PROVIDERS

10.1.    Aldevron

10.2.    Biomay

10.3.    bioSYNTHESIS

10.4.    eTheRNA

10.5.    Eurogentec

10.6.    TriLink BioTechnologies

11. COMPANY PROFILES: mRNA SYNTHESIS KIT PROVIDERS

11.1.    APExBIO

11.2.    CELLSCRIPT

11.3.    Jena Biosciences

11.4.    New England Biolabs

11.5.    Thermo Fisher Scientific

12. CLINICAL TRIAL ANALYSIS

12.1.    Methodology

12.2.    mRNA-based Therapeutics / Vaccines: Clinical Trial Analysis

12.2.1.             Analysis by Trial Registration Year

12.2.2              Analysis by Trial Status

12.2.3.             Analysis by Trial Registration Year and Patients Enrolled

12.2.4.             Analysis by Trial Registration Year and Trial Status

12.2.5.             Analysis by Trial Phase

12.2.6.             Analysis by Target Patient Population

12.2.7.             Analysis by Therapeutic Area

12.2.8.             Analysis by Type of Sponsor / Collaborator

12.2.9.             Most Active Players: Analysis by Number of Trials

12.2.10.           Analysis by Region

13. PARTNERSHIP AND COLLABORATIONS

13.1.    Partnership Models                

13.2.    mRNA Synthesis and Manufacturing: Partnerships and Collaborations

13.1.1.             Analysis by Year of Partnership

13.1.2.             Analysis by Type of Partnership

13.1.3.             Analysis by Type of Product

13.1.4.             Analysis by Type of Partner

13.1.5.             Most Active Players: Analysis by Number of Partnerships

13.1.6.             Analysis by Local and International Agreements

13.1.7.             Analysis by Intercontinental and Intracontinental Agreements

13.1.8.             Analysis by Region

14. LIKELY PARTNERS ANALYSIS

14.1.    Methodology

14.2.    Likely Partners based in North America

14.3.    Likely Partners based in Europe

14.4.    Likely Partners based in Asia Pacific and Rest of the World

15. BIG PHARMA INITIATIVES

15.1.    Methodology

15.2.    Big Pharma Players: List of mRNA-based Therapeutics / Vaccines Focused Initiatives

15.3.    Competitive Benchmarking of Big Pharma Players

15.3.1. Harvey Ball Analysis

15.3.2. Spider Web Analysis

16. MARKET FORECAST

16.1.    Chapter Overview

16.2.    Key Assumptions and Forecast Methodology

16.3.    Global mRNA Synthesis and Manufacturing Market, 2022-2035

16.3.1.             mRNA Synthesis and Manufacturing Market, 2022-2035: Distribution by Type of Product

16.3.1.1. mRNA Synthesis and Manufacturing Market for Drug Substances (APIs), 2022-2035

16.3.1.2. mRNA Synthesis and Manufacturing Market for Drug Products (FDFs), 2022-2035

16.3.2.              mRNA Synthesis and Manufacturing Market, 2022-2035: Distribution by Application Area,

16.3.2.1. mRNA Synthesis and Manufacturing Market for mRNA-based Vaccines, 2022-2035

16.3.2.2. mRNA Synthesis and Manufacturing Market for mRNA-based Therapeutics, 2022-2035

16.3.3. mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area, 2022, 2025 and 2035

16.3.3.1. mRNA Synthesis and Manufacturing Market for Infectious Diseases, 2022-2035

16.3.3.1. mRNA Synthesis and Manufacturing Market for Oncological Disorders, 2022-2035

16.3.3.1. mRNA Synthesis and Manufacturing Market for Other Diseases, 2022-2035

16.3.4.             mRNA Synthesis and Manufacturing Market: Distribution by Geography, 2025 and 2035 (USD Billion)

16.3.4.1. mRNA Synthesis and Manufacturing Market in North America, 2022-2035

16.3.4.2. mRNA Synthesis and Manufacturing Market in Europe, 2022-2035

16.3.4.3. mRNA Synthesis and Manufacturing Market in Asia Pacific, 2022-2035

16.3.4.4. mRNA Synthesis and Manufacturing Market in Latin America, 2022-2035

16.3.4.5. mRNA Synthesis and Manufacturing Market in MENA, 2022-2035

16.3.4.6. mRNA Synthesis and Manufacturing Market in Rest of the World, 2022-2035

17. EXECUTIVE INSIGHTS

18. APPENDIX 1: TABULATED DATA

19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

To view more details on this report, click on the link

https://www.rootsanalysis.com/reports/mrna-synthesis-and-manufacturing-market.html

You may also be interested in the following titles:

You may also like to learn what our experts are sharing in Roots educational series:

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415

Ben.johnson@rootsanalysis.com